当前位置:
X-MOL 学术
›
Ann. Hematol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Radioimmunotherapy for mantle cell lymphoma: 5-year follow-up of 90 patients from the international RIT registry.
Annals of Hematology ( IF 3.5 ) Pub Date : 2020-03-03 , DOI: 10.1007/s00277-020-03956-0 Karin Hohloch 1, 2 , Christine Windemuth-Kieselbach 3 , Pier Luigi Zinzani 4 , Roberto Cacchione 5 , Wojciech Jurczak 6 , C Suh 7 , Lorenz Trümper 2 , Christian W Scholz 8
Annals of Hematology ( IF 3.5 ) Pub Date : 2020-03-03 , DOI: 10.1007/s00277-020-03956-0 Karin Hohloch 1, 2 , Christine Windemuth-Kieselbach 3 , Pier Luigi Zinzani 4 , Roberto Cacchione 5 , Wojciech Jurczak 6 , C Suh 7 , Lorenz Trümper 2 , Christian W Scholz 8
Affiliation
To assess the efficacy of radioimmunotherapy (RIT) with 90yttrium-ibrutinib-tiuxetan (90Y-IT) in mantle cell lymphoma, data from 90 patients registered in the RIT Network with a median follow-up (FU) of 5.5 years after RIT were evaluated. 90Y-IT was given as first-line therapy in 45 (50%) and for relapse in 45 (50%) patients. Most patients received 90Y-IT as consolidation after chemoimmunotherapy in first line (98%) and in relapse (53%). As a first-line treatment, 30 patients (pts.) (67%) achieved CR, 10 pts. (22%) PR%. and 1 pt. (2%) PD, and for 4 pts. (9%), no response data was available. At relapse, CR was achieved in 17 pts. (38%), PR in 6 pts. (13%), SD in 2 pts. (4%), and 6 pts. (13%) had PD, while the response was not documented for 14 pts. (31%). After a median FU of 5.5 years, median PFS for all patients was 2.11 (95% CI, 1.03-2.32) years, and median OS was 4.05 (95% CI, 2.79-7.21) years. Eleven pts. (12.2%) developed second malignancy. In conclusion, this is the largest report of MCL pts. treated with 90Y-IT to date. 90Y-IT was most often used as consolidation after first- and second-line chemotherapy and may improve the results achieved using chemoimmunotherapy alone. However, the results are less encouraging compared to treatment with small molecules such as ibrutinib.
中文翻译:
外套细胞淋巴瘤的放射免疫疗法:国际RIT登记处对90名患者进行了5年随访。
为了评估90yttrium-ibrutinib-tiuxetan(90Y-IT)在套细胞淋巴瘤中的放射免疫疗法(RIT)的疗效,评估了RIT网络中注册的90例患者的数据,中位随访时间(FU)为RIT后5.5年。一线疗法90Y-IT在45(50%)位患者中复发,在45(50%)位患者中复发。大多数患者在一线(98%)和复发(53%)接受化学免疫治疗后接受90Y-IT巩固治疗。作为一线治疗,有30位患者(pts。)(67%)达到CR,10分。(22%)PR%。和1点 (2%)PD,为4分。(9%),没有可用的回应数据。复发时,CR达到17分。(38%),PR为6分。(13%),标准偏差为2分。(4%),和6分。(13%)的患者有PD,而14例患者的反应均未记录。(31%)。在FU的中位数为5.5年之后,所有患者的中位PFS为2.11(95%CI,1.03-2.32)年,OS中位数为4.05年(95%CI,2.79-7.21)年。十一分 (12.2%)患上第二恶性肿瘤。总之,这是MCL pts的最大报告。迄今为止,已使用90Y-IT处理过。一线和二线化疗后最常使用90Y-IT巩固治疗,可能会改善仅使用化学免疫疗法所获得的结果。但是,与使用小分子药物如依鲁替尼治疗相比,结果不那么令人鼓舞。
更新日期:2020-03-03
中文翻译:
外套细胞淋巴瘤的放射免疫疗法:国际RIT登记处对90名患者进行了5年随访。
为了评估90yttrium-ibrutinib-tiuxetan(90Y-IT)在套细胞淋巴瘤中的放射免疫疗法(RIT)的疗效,评估了RIT网络中注册的90例患者的数据,中位随访时间(FU)为RIT后5.5年。一线疗法90Y-IT在45(50%)位患者中复发,在45(50%)位患者中复发。大多数患者在一线(98%)和复发(53%)接受化学免疫治疗后接受90Y-IT巩固治疗。作为一线治疗,有30位患者(pts。)(67%)达到CR,10分。(22%)PR%。和1点 (2%)PD,为4分。(9%),没有可用的回应数据。复发时,CR达到17分。(38%),PR为6分。(13%),标准偏差为2分。(4%),和6分。(13%)的患者有PD,而14例患者的反应均未记录。(31%)。在FU的中位数为5.5年之后,所有患者的中位PFS为2.11(95%CI,1.03-2.32)年,OS中位数为4.05年(95%CI,2.79-7.21)年。十一分 (12.2%)患上第二恶性肿瘤。总之,这是MCL pts的最大报告。迄今为止,已使用90Y-IT处理过。一线和二线化疗后最常使用90Y-IT巩固治疗,可能会改善仅使用化学免疫疗法所获得的结果。但是,与使用小分子药物如依鲁替尼治疗相比,结果不那么令人鼓舞。